# TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz

> **NCT00023413** · PHASE2 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 20 (—)

## Conditions studied

- HIV Infections
- Tuberculosis

## Interventions

- **DRUG:** Rifabutin
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT00023413
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** 20 (—)
- **Last updated:** 2012-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023413, "TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00023413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*